0.01
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Algorae Pharmaceuticals
Its shares trade on ASX under the ticker 1AI.AX. It has been listed since 1 September 2004. In the fiscal year to 30 June 2025, it reported revenue of A$141,100 and a net loss of A$803,000. At that date it held total assets of A$2.4m and shareholders' equity of A$2.2m.
Algorae Pharmaceuticals Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The firm is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Sept 2004
- Website
- lctglobal.com ↗
Leadership
Pay as last reported
- Mr. David HainsworthExecutive Chairman of the Board, since 2022
- Mr. Daya UkaChief Financial Officer
- Dr. Belinda Di BartoloChief Operating Officer
- Dr. James MckennaChief Scientific Officer
- Dr. Carolyn SueChief Medical Officer, since 2019
- Ms. Jennifer VoonCompany Secretary
- Mr. Bradley DilkesDirector
- Mr. Bradley LathamNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AlgoraeOS leverages advanced computational tools for novel therapeutic insights.
- NTCELL targets Parkinson's disease with alginate coated capsules for brain treatment.
- AI-116 combines CBD with off-patent pharmaceuticals for dementia treatment.
Weaknesses
- Algorae Pharmaceuticals Limited was formerly Living Cell Technologies Limited.
- The company's drug candidates are in early development stages.
- The firm focuses on under met medical needs with limited market presence.
Opportunities
- AlgoraeOS platform can accelerate therapeutic programs through in-silico insights.
- AI-116 combination drug candidate targets dementia with CBD and off-patent drugs.
- NTCELL offers a novel approach for Parkinson's disease treatment in Australia.
Threats
- The company's IPO was on 1 September 2004, a long time ago.
- Biotechnology industry faces high development costs and regulatory hurdles.
- Under met medical needs may not attract sufficient investment funding.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.